Valeo Financial Advisors LLC Cuts Position in Stryker Co. (NYSE:SYK)

Valeo Financial Advisors LLC trimmed its position in shares of Stryker Co. (NYSE:SYK) by 3.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,603 shares of the medical technology company’s stock after selling 244 shares during the period. Valeo Financial Advisors LLC’s holdings in Stryker were worth $2,721,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Harbor Investment Advisory LLC boosted its holdings in Stryker by 0.4% in the first quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock valued at $2,499,000 after purchasing an additional 31 shares in the last quarter. Bremer Bank National Association boosted its holdings in Stryker by 4.0% in the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after purchasing an additional 34 shares in the last quarter. Simon Quick Advisors LLC boosted its holdings in Stryker by 3.0% in the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after purchasing an additional 34 shares in the last quarter. Consolidated Portfolio Review Corp boosted its holdings in Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 34 shares in the last quarter. Finally, FourThought Financial Partners LLC boosted its holdings in Stryker by 3.3% in the fourth quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after purchasing an additional 34 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Barclays increased their price objective on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. UBS Group increased their price objective on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Evercore ISI decreased their price objective on Stryker from $370.00 to $365.00 and set an “outperform” rating for the company in a report on Tuesday. TD Cowen increased their price objective on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Finally, Citigroup increased their price objective on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $370.32.

Stryker Trading Down 0.7 %

NYSE:SYK opened at $332.07 on Thursday. The company has a market capitalization of $126.50 billion, a PE ratio of 37.91, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The stock has a fifty day simple moving average of $337.55 and a 200-day simple moving average of $334.50.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.14. The business had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.14 EPS. On average, equities research analysts expect that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.96%. The ex-dividend date is Friday, June 28th. Stryker’s payout ratio is 36.53%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.